



**SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED**

PO Box 309, Uglan House  
Grand Cayman, KY1-1104  
Cayman Islands

**SILVER PEGASUS INVESTMENT LIMITED**

Walkers Corporate Limited  
190 Elgin Avenue  
George Town  
Grand Cayman, KY1-9008  
Cayman Islands

24 May 2024

Dear Sirs,

**(1) PROPOSAL FOR THE PRIVATISATION OF  
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED  
BY SILVER PEGASUS INVESTMENT LIMITED  
BY WAY OF A SCHEME OF ARRANGEMENT  
(UNDER SECTION 86 OF THE COMPANIES ACT)**

**(2) PROPOSED WITHDRAWAL OF LISTING OF  
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED**

**(3) SPECIAL DEAL RELATING TO ROLLOVER ARRANGEMENTS**

We refer to the scheme document jointly issued by SciClone Pharmaceuticals (Holdings) Limited and Silver Pegasus Investment Limited dated 24 May 2024 in relation to, among other things, the captioned matters (the “**Scheme Document**”). Capitalised terms used in this letter shall have the same meanings as those defined in the Scheme Document, unless the context requires otherwise.

We, CICC, as the financial adviser to the Offeror in connection with the Proposal, hereby confirm that we have given and have not withdrawn our written consent to the issue of the Scheme Document with the inclusion therein of our opinions, and the references to our name, opinions, logo and qualifications in the form and context in which they respectively appear in the Scheme Document.

We hereby further consent to, and confirm that we have not withdrawn our written consent to, this letter being made available for public inspection as described in the section headed “*10. Documents Available for Inspection*” in Appendix II (General Information) to the Scheme Document.

Yours faithfully

for and on behalf of  
China International Capital Corporation Hong Kong Securities Limited



---

Name: David CHING  
Title: Executive Director